Newscast – Page 160 – media

Lilly and CureVac Announce Global Collaboration to Develop mRNA Cancer Vaccines

Eli Lilly and Company (LLY) and CureVac AG have announced a global immuno-oncology collaboration focused on the development and commercialization of up to five potential cancer vaccine products based on CureVac's proprietary RNActive® technology. The companies will use messenger RNA (mRNA) technology that targets tumor neoantigens for a more robust anti-cancer immune response.
- Source: Finance
- 667
- October 20, 2017
immune Market Views mRNA vaccine
Kite’s Yescarta™ (Axicabtagene Ciloleucel) Becomes First CAR T Therapy Approved by the FDA

Kite, a Gilead Company, announced that the U.S. Food and Drug Administration (FDA) has granted regular approval to Yescarta™ (axicabtagene ciloleucel), the first chimeric antigen receptor T cell (CAR T) therapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma (PMBCL), high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma (transformed follicular lymphoma, or TFL). Yescarta is not indicated for the treatment of patients with primary central nervous system lymphoma.
- Source: Businesswire
- 691
- October 20, 2017
B-cell lymphoma CAR–T FDA Market Views Yescarta
H7N9 influenza is both lethal and transmissible in animal model for flu

For the first time, Kawaoka says, his team has identified an influenza virus strain that is both transmissible between ferrets (the best animal model proxy for human influenza infections) and lethal, both in the animal originally infected and in otherwise healthy ferrets in close contact with these infected animals.
- Source: Medicalxpress
- 988
- October 20, 2017
H7N9 Researches
Genetic testing startup Prenetics raised $40M in Series B round led by Alibaba’s Hong Kong fund and Beyond Ventures

Genetic testing startup Prenetics has raised $40 million in a Series B funding round led by Hong Kong-based venture capital fund Beyond Ventures and the Alibaba Hong Kong Entrepreneurs Fund.
- Source: Mastsea
- 568
- October 19, 2017
Artificial Intelligence Market Views Series
GlaxoSmithKline wins first-ever nod for blockbuster vaccine prospect Shingrix

Just as GlaxoSmithKline nears a decision from the U.S. FDA for its key shingles vaccine, Shingrix, Canada has become the first country to approve the shot—and it's a key piece of CEO Emma Walmsley's prescription for growth at the drugmaker.
- Source: fiercepharma
- 617
- October 19, 2017
New Approvals shingles vaccine
U.S. pressing India to avoid capping medical device prices, allow withdrawals

Indian Prime Minister Narendra Modi’s government has in recent months slashed prices of medical devices such as knee implants and heart stents by up to 75 percent to make them more affordable.
- Source: reuters
- 443
- October 19, 2017
Market Views medical device
Hormone therapy for prostate cancer increases cardiac risk

Androgen-deprivation therapy, which is a common treatment for prostate cancer, has been tentatively linked with an increased risk of cardiovascular disease. A new study solidifies these concerns.
- Source: medicalnewstoday
- 621
- October 19, 2017
cancer cardiovascular prostate Researches
FDA Okays Another CAR T-Cell Therapy

The FDA has approved a second chimeric antigen receptor (CAR) T-cell therapy for cancer: Kite Pharma's axicabtagene ciloleucel (Yescarta) for the treatment of certain types of refractory large B-cell lymphoma, the agency announced.
- Source: medpagetoday
- 757
- October 19, 2017
cancer CAR–T FDA New Approvals
New findings explain how UV rays trigger skin cancer

Melanoma, a cancer of skin pigment cells called melanocytes, will strike an estimated 87,110 people in the U.S. in 2017, according to the Centers for Disease Control and Prevention. A fraction of those melanomas come from pre-existing moles, but the majority of them come from sources unknown - until now.
- Source: Medicalxpress
- 579
- October 19, 2017
Melanoma
AstraZeneca admits cancer data for acquired drug was fabricated

AstraZeneca has revealed that early-stage data concerning the efficacy of its acquired drug acalabrutinib in the treatment of blood cancers and solid tumours was invented and falsified.
- Source: Pharmafile
- 646
- October 19, 2017
acalabrutinib AstraZeneca blood cancer solid tumour

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.